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Babesiosis is a tick-borne disease caused by eukaryotic Babesia parasites which
are morphologically similar to Plasmodium falciparum, the causative agent of
malaria in humans. Like Plasmodium, different species of Babesia are tuned to
infect different mammalian hosts, including rats, dogs, horses and cattle. Most
species of Plasmodium and Babesia possess an essential bifunctional enzyme
for nucleotide synthesis and folate metabolism: dihydrofolate reductase-
thymidylate synthase. Although thymidylate synthase is highly conserved across
organisms, the bifunctional form of this enzyme is relatively uncommon in
nature. The structural characterization of dihydrofolate reductase-thymidylate
synthase in Babesia bovis, the causative agent of babesiosis in livestock cattle,
is reported here. The apo state is compared with structures that contain dUMP,
NADP and two different antifolate inhibitors: pemetrexed and raltitrexed. The
complexes reveal modes of binding similar to that seen in drug-resistant malaria
strains and point to the utility of applying structural studies with proven cancer
chemotherapies towards infectious disease research.
1. Introduction
Babesiosis is an infectious disease affecting humans, cattle and other
mammals caused by protozoal Babesia piroplasms. Although of less
impact than malaria on human health, various species of this api-
complexan are thought to be the most common form of blood-borne
parasite after trypanosomes (Parola & Raoult, 2001; Hunfeld et al.,
2008; Homer et al., 2000). Like Plasmodium falciparum, the causative
agent of malaria in humans, Babesia species generate asexual mero-
zoites through binary ﬁssion of red blood cells (RBCs) after infection.
Both pathogens also develop mature gametocytes in the host,
allowing re-infection and sexual reproduction within their respective
transmission vectors: Anopheles mosquitoes for Plasmodium and
Ixodes ticks for Babesia (Parola & Raoult, 2001; Florens et al., 2002).
Human babesiosis is somewhat regional, consisting mainly of infec-
tions with B. divergens in Europe and B. microti in the Americas.
However, the infection of commercial livestock and other domes-
ticated animals with B. bigemina and B. bovis has been reported on
nearly every continent in both temperate and equatorial climates
(Bock et al., 2004). Thus, Babesia represents an emerging threat to
commercial livestock and an increasing cause for concern in humans,
with recent reports of resistance in B. microti to azithromycin–
atovaquone drug therapy (Wormser et al., 2010). For these reasons,
babesiosis and other tick-borne illnesses have become a priority with
the National Institute for Allergy and Infectious Disease (NIAID),
prompting research into the development of vaccines and new
chemotherapeutics for treatment. Owing to its genetic and morpho-
logical similarity to Plasmodium species, drugs which have proven
effective in treating malaria may play a critical role in this research
(Bock et al., 2004; Brayton et al., 2007; Homer et al., 2000; Hunfeld et
al., 2008). Likewise, mechanisms of resistance which have already
appeared in malaria owing to various environmental pressures mayprovide vital information at the outset of designing novel treatments
for Babesia infections.
In this work, we describe the structural features of dihydrofolate
reductase-thymidylate synthase from B. bovis (BbDHFR-TS), the
causative agent of babesiosis in cattle. This bifunctional enzyme is
inhibited by pyrimethamine and other antifolates in P. falciparum
(PfDHFR-TS), to which multiple strains of malaria have become
resistant (Peterson et al., 1988; Yuthavong et al., 2005; Foote et al.,
1990). The enzyme thymidylate synthase (TS) catalyzes the methyl-
ation of deoxyuridine 50-monophosphate (dUMP) to thymidine
50-monophosphate (thymidine) employing the cofactor N
5,N
10-
methylene-5,6,7,8-tetrahydrofolate (mTHF) as both a methylene
donor and a reductant (Carreras & Santi, 1995; Friedkin & Roberts,
1956). The spent cofactor dihydrofolate (DHF) is then passed
through dihydrofolate reductase (DHFR) and serine hydroxy-
methyltransferase in order to regenerate mTHF (Carreras & Santi,
1995). Many species possess the means to salvage and replenish
thymidine from DNA-degradation products, the action of thymidine
kinase being a primary example (Chen & Prusoff, 1978). However,
inhibition of thymidylate synthase is sufﬁcient to toxify cells which
are rapidly dividing (Harrap et al., 1989; Jackman & Calvert, 1995).
We have obtained the apo structure of BbDHFR-TS as well as
complexes of this protein bound to raltitrexed and pemetrexed
(Fig. 1), two antifolates with proven activity as cancer chemother-
apeutics (Jackman & Calvert, 1995; Jackman et al., 1991; Taylor et al.,
1992). Using this trio of structures, we discuss key residues in
BbDHFR-TS which accommodate small molecules and reveal
different conformational states of the bound inhibitors in the DHFR
subunit. These structures may provide a useful starting point for
DHFR-TS drug design and currently comprise a signiﬁcant structural
contribution to the Protein Data Bank (PDB; Berman et al., 2000,
2003) for B. bovis gene products.
2. Methods
2.1. Expression and purification
Dihydrofolate reductase-thymidylate synthase (BaboA.01191.a;
XP_001609606.1) from the Texas T2Bo isolate of B. bovis (Brayton et
al., 2007) spanning the full-length protein from residues 1 to 511 was
cloned into a modiﬁed pET28 vector. This construct (BbDHFR-TS)
was engineered for protein expression in Gene Composer and cloned
using Polymerase Incomplete Primer Extension (PIPE) cloning into a
vector engineered to donate an amino-terminal 6 His-Smt tag with
a protease cleavage site to the ORF (Lorimer et al., 2009; Klock &
Lesley, 2009; Mossessova & Lima, 2000). The ﬁnal DHFR-TS protein
contains MSHHHHHHSGEVKPEVKPETHINLKVSDGSSEIFFK-
IKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPE-
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Figure 1
Substrates and cofactors of dihydrofolate reductase (DHFR) [dihydrofolate (DHF) and nicotinamide adenine dinucleotide phosphate (NADP), respectively] and
thymidylate synthase (TS) [50-deoxyuridine monophosphate (dUMP) and N
5,N
10-methylene-5,6,7,8-tetrahydrofolate (mTHF), respectively]. Also shown are the two folate
analogs and TS inhibitors raltitrexed (RTX) and pemetrexed (PTX).DLDMEDNDIIEAHREQIGGS–priortotheN-terminalmethionine
of the native sequence. BbDHFR-TS was expressed in Escherichia
coli BL21 (DE3) cells in autoinduction medium (Terriﬁc Broth plus
Novagen Overnight Express System 1) in a LEX Bioreactor at 293 K
for 65 h. Each of several batches of BbDHFR-TS protein was puriﬁed
in the same manner. The ﬁrst batch started from 26 g frozen cell paste
and was resuspended in 150 ml lysis buffer {200 mM sodium chloride,
50 mM l-arginine, 25 mM tris(hydroxymethyl)aminomethane (Tris),
10 mM imidazole, 0.5%(v/v) glycerol, 0.02%(w/v) 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate (CHAPS) pH 8.0 with
5 ml Benzonase, 100 mg lysozyme and one EDTA-free protease-
inhibitor tablet (Roche) added}. The cells were lysed by sonication
(70% power for 3 min) and the solution was clariﬁed by centrifuga-
tion at an RCF of 4000g for 35 min at 277 K.
The clariﬁed lysate was initially puriﬁed by nickel-afﬁnity chro-
matography using the Protein Maker from Emerald BioSystems
(Smith et al., 2011). The column was washed with wash buffer
[200 mM NaCl, 25 mM Tris, 50 mM arginine, 10 mM imidazole,
1.0 mM tris(2-carboxyethyl)phosphine (TCEP), 0.25%(v/v) glycerol
pH 8.0] and eluted with wash buffer containing 500 mM imidazole.
Fractions containing the protein were pooled, dialyzed into wash
buffer and treated with ubiquitin-like protease 1 (Ulp1) at 1 mg ml
 1
for every 5 mg protein overnight at 277 K. Ulp1 cleaves the protein
between the N-terminal methionine of BbDHFR-TS and the
C-terminal serine of the QIGGS tag sequence, leaving no remnant of
the tag on the protein. Samples were passed over a 1.0 ml HisTrap
nickel column using a syringe pump to bind uncleaved protein, the
cleaved 6 His-Smt tag and 6 His-tagged Ulp1, allowing puriﬁed
BbDHFR-TS to be collected in the ﬂowthrough. The protein was
then dialyzed overnight into size-exclusion (SEC) buffer [200 mM
NaCl, 25 mM Tris, 1 mM TCEP and 1%(v/v) glycerol pH 8.0] and
concentrated into a 5 ml volume for additional puriﬁcation by HiPrep
Sephacryl S-100 size-exclusion chromatography. Fractions were
analyzed by SDS–PAGE and pooled for highest purity. The
BbDHFR-TS protein sample was concentrated, ﬂash-frozen in liquid
nitrogen and stored at 193 K in 100 ml aliquots for crystallization
experiments.
2.2. Crystallization
Initial sitting-drop vapor-diffusion crystallization trials were set up
at 289 Kusing the JCSG+, Wizard, PACTand Cryo Full sparse-matrix
screens from Emerald BioSystems and the Index HT sparse-matrix
screen from Hampton Research. 0.4 ml protein solution was mixed
with 0.4 ml reservoir solution and equilibrated against 100 ml reservoir
solution using 96-well Compact Jr plates from Emerald BioSystems.
The protein solution consisted of 11 mg ml
 1 BbDHFR-TS in SEC
buffer and crystal conditions were optimized using the Microcapillary
Protein Crystallization System (MPCS) from Emerald BioSystems
(Gerdts et al., 2008, 2010; Christensen et al., 2011). The BbDHFR-TS
crystal used to solve the apo structure (PDB entry 3i3r) was obtained
from a crystal card running a microﬂuidic gradient focused at
20%(w/v) polyethylene glycol (PEG) 8000 and 100 mMN -cyclo-
hexyl-2-aminoethanesulfonic acid (CHES) pH 9.5. Additional crys-
tals of BbDHFR-TS were prepared by sitting-drop vapor diffusion
using 0.8 ml drops of a 1:1 mixture of crystallization buffer [20%(w/v)
PEG 8000, 100 mM CHES pH 9.5] and a fresh batch of protein at
20 mg ml
 1 in SEC buffer. Unlike the previous batch crystallized
via MPCS, the new BbDHFR-TS protein sample yielded crystals by
sitting-drop vapor diffusion which retained the cofactor NADP
throughout puriﬁcation. The pemetrexed-bound structure (PDB
entry 3k2h) was obtained by soaking preformed crystals ofBbDHFR-
TS prepared by sitting-drop vapor diffusion in fresh drops consisting
of 2.0 mM dUMP and 2 mM pemetrexed in 100% crystallization
buffer, with 20 ml buffer in the reservoir. Despite repeated attempts
to soak raltitrexed into preformed crystals of BbDHFR-TS, none
yielded high-quality crystals with unambiguous electron density for
this small molecule. Therefore, cocrystallization trials were conducted
by sitting-drop vapor diffusion at 289 K using Wizard, PACT, JCSG+
and Index HT sparse-matrix screens. Drops were prepared by mixing
0.4 ml crystallant with 0.4 ml solution consisting of 2 mM dUMP, 2 mM
NADP, 5 mM raltitrexed and 20 mg ml
 1 protein in SEC buffer, with
100 ml crystallization solution in the reservoir. The crystals used for
structure determination (PDB entry 3nrr) were obtained from crys-
tallization buffer consisting of 20 mM magnesium chloride, 100 mM
HEPES and 22%(w/v) poly(acrylic acid) sodium salt 5100 at pH 7.5.
2.3. Data collection and structure determination
All crystals of BbDHFR-TS were looped and cryoprotected in
their respective mother liquors spiked with 25%(v/v) ethylene glycol
prior to freezing in liquid nitrogen for X-ray diffraction experiments.
The data set for PDB entry 3k2h was collected in-house using a
Rigaku SuperBright FR-E+ X-ray generator with Osmic VariMax HF
optics and a Saturn 944+ CCD detector. Data sets for PDB entries
3i3r and 3nrr were collected at the ALS synchrotron on beamlines
5.0.2 and 5.0.1, respectively. Diffraction data were reduced with either
HKL-2000 (Otwinowski & Minor, 1997) or XDS/XSCALE (Kabsch,
1988, 1993, 2010). The apo structure was solved by molecular
replacement using Phaser (McCoy et al., 2007) from the CCP4 suite of
programs (Winn et al., 2011) with molecule A of DHFR-TS from
Cryptosporidium hominis (PDB entry 1qzf; O’Neil et al., 2003) as
the search model. The pemetrexed-bound structure was solved by
molecular replacement using the apo structure of BbDHFR-TS as the
search model; the raltitrexed-bound structure was solved using the
pemetrexed complex in an analogous fashion. All crystal structures
structural communications
1072 Begley et al.   Dihydrofolate reductase-thymidylate synthase Acta Cryst. (2011). F67, 1070–1077
Table 1
Data-collection statistics for crystal structures of BbDHFR-TS.
Values in parentheses are for the highest of 20 resolution shells.
PDB code 3i3r 3k2h 3nrr
Space group P1 P1 P1
Matthews coefﬁcient VM
(A ˚ 3 Da
 1)
2.60 2.56 2.60
Unit-cell parameters
a (A ˚ ) 52.54 51.14 51.33
b (A ˚ ) 83.48 83.20 83.83
c (A ˚ ) 84.19 83.38 83.92
  ( ) 119.0 119.7 119.6
  ( ) 98.0 90.9 90.3
  ( ) 100.7 101.7 102.0
Diffraction source ALS 5.0.2 Rotating anode ALS 5.0.1
Diffraction protocol Single wavelength Single wavelength Single wavelength
Monochromator Cryocooled crystal VariMax HF Asymmetric curved
crystal
Wavelength (A ˚ ) 1.00 1.5418 0.97946
Detector ADSC Quantum
315 CCD
Rigaku Saturn
944+ CCD
ADSC Quantum
315 CCD
Temperature (K) 100 100 100
Resolution range (A ˚ ) 72.20–2.35
(2.41–2.35)
50.00–2.20
(2.24–2.20)
50.00–1.80
(1.83–1.80)
Total unique reﬂections 47995 58064 108796
Completeness (%) 96.8 (96.7) 98.5 (82.6) 97.2 (95.9)
Multiplicity 2.9 (2.9) 4.0 (2.7) 2.0 (2.0)
Mean I/ (I) 9.6 (2.2) 15.4 (3.2) 12.3 (2.4)
Rmerge† 0.099 (0.551) 0.096 (0.286) 0.060 (0.354)
Phasing method Molecular
replacement
Molecular
replacement
Molecular
replacement
Starting-model data set 1qzf 3i3r 3k2h
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.were initially rebuilt with ARP/wARP (Langer et al., 2008) followed
by iterative rounds of reﬁnement in REFMAC5 (Murshudov et al.,
1997) and manual model building using the Crystallographic Object-
Oriented Toolkit (Coot; Emsley & Cowtan, 2004). Water molecules
were placed in the model using standard  -cutoff values and distances
from the protein as deﬁned by Coot. During reﬁnement, every water
molecule in every structure was visually assessed and suspicious
waters were removed based on inappropriate distances or   levels
using both |Fo|   |Fc| and 2|Fo|   |Fc| density maps. Each structure was
evaluated using MolProbity (Chen et al., 2010) and manually checked
by internal peer review prior to structure validation and deposition in
the Protein Data Bank (Berman et al., 2000, 2003). Data-collection
details are listed in Table 1 and reﬁnement statistics for all three
structures are contained in Table 2, with good geometric ﬁtness
according to analysis with MolProbity (Chen et al., 2010). Given the
resolution limits for the apo structure, Rwork and Rfree still fall within
acceptable guidelines given the disordered regions of the linker
groups.
3. Results and discussion
3.1. Overall structure of BbDHFR-TS
BbDHFR-TS is a homodimer that exhibits the classical dimeric
interface seen in other structures of ThyA thymidylate synthase and
bifunctional DHFR-TS enzymes (Costi et al., 2005; Finer-Moore et al.,
2003; O’Neil et al., 2003; Yuthavong et al., 2005; Schiffer et al., 1995).
This 511-residue, 58.2 kDa bifunctional enzyme consists of a di-
hydrofolate reductase (DHFR) subunit at the N-terminus and a
thymidylate synthase (TS) subunit at the C-terminus connected by a
linker (Fig. 2). The ﬁrst 186 N-terminal residues comprise the DHFR
subunit, a nine-stranded  -sheet surrounded by ﬂexible loops and
four short  -helices. A 40-residue linker is made of two long ﬂexible
chains with a two-turn  -helix in the middle and connects the DHFR
and TS domains. The remaining 285 C-terminal amino acids encom-
pass the TS monomer, which consists of a warped four-stranded
 -sheet forming the TS–TS dimeric interface, together with several
 -helices and loops near the active site. BbDHFR-TS is an obligate
dimer, with two arginine side chains (Arg3730 and Arg3740) from a
ﬂexible loop in one protomer making contact with the terminal
phosphate of the substrate dUMP in the opposite protomer (Fig. 3).
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Table 2
Reﬁnement statistics for crystal structures of BbDHFR-TS.
Values in parentheses are for the highest of 20 resolution shells.
PDB code 3i3r 3k2h 3nrr
Resolution range (A ˚ ) 19.69–2.35
(2.41–2.35)
35.20–2.19
(2.25–2.19)
19.94–1.79
(1.83–1.79)
No. of reﬂections above   cutoff
in ﬁnal cycle
47995 57443 104245
Rcryst† 0.205 0.192 0.196
No. of reﬂections for Rfree 2440 (181) 2917 (183) 5573 (364)
Final Rfree† 0.251 (0.353) 0.239 (0.263) 0.236 (0.270)
Overall average B factor (A ˚ 2) 23.3 16.7 19.8
Average ligand B factor (A ˚ 2) 37.89 25.26 23.31
No. of protein atoms 7607 8072 7965
No. of ligand atoms 2 280 329
No. of solvent atoms 253 727 1025
Total No. of atoms 7862 9079 9319
Residues in favored region (%) 96.5 97.3 98.0
Residues in allowed region (%) 99.7 100 100
Residues in disallowed region (%) 0.3 0.0 0.0
MolProbity score [percentile] 1.97 [92nd] 1.69 [96th] 1.36 [97th]
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of
the reﬂections, which were omitted from the reﬁnement (Winn et al., 2011).
Figure 2
Crystal structures of bifunctional homodimeric dihydrofolate reductase-
thymidylate synthase from B. bovis (BbDHFR-TS). The DHFR subunit of each
protomer (green, pink) is connected to a C-terminal TSsubunit (violet, yellow) by a
40-residue linker (cyan, gray). The protein in the apo state (top; PDB entry 3i3r)
has a single chlorine ion in each TS active site (green spheres). Below are structures
of BbDHFR-TS bound to dUMP, NADP and pemetrexed (middle; PDB entry
3k2h) and complexed with dUMP, NADP and raltitrexed (bottom; PDB entry
3nrr). Identical ligands are bound to protomer A (white, left) and protomer B
(black, right) in each homodimer complex. Electron density (green mesh) is
depicted for protomer A ligands at a 2.5  contour level carved from a 1.6 A ˚ atomic
radius of the |Fo|   |Fc| maps using phases calculated from models lacking the
ligand. This ﬁgure was created using CCP4( W i n net al., 2011) and PyMOL
(DeLano, 2002).Mutational studies have demonstrated these residues are essential for
catalytic activity in TS and are 100% conserved across known
sequences (Carreras & Santi, 1995; Michaels et al., 1990). Two addi-
tional arginines from the active-site protomer (Arg248 and Arg413)
are also conserved and help to stabilize the deeply buried phosphate
of the substrate (Fig. 3). This highly charged positive cavity in TS
often leads to binding of phosphates and other anions present in the
crystallization conditions and explains the chlorine ions bound in our
apo structure of BbDHFR-TS (PDB entry 3i3r; Fig. 2).
The DHFR subunits of BbDHFR-TS do not make contact with
each other in the quaternary structure and are observed to be
approximately 25 A ˚ apart at their closest point. However, the linker
from one BbDHFR-TS protomer stretches across to make contact
with the DHFR subunit of the opposite protomer (Fig. 2). This places
the enzyme in the ‘long-linker’ family of bifunctional DHFR-TSs
together with those ofother apicomplexans, such as P. falciparum and
C. hominis, as compared with the short-linker family seen for
Leishmania major (O’Neil et al., 2003). The  -helix in the middle of
the linker creates a hydrophobic recognition point, ﬁtting into a
nonpolar solvent-exposed groove created by Phe40 and Tyr47 on the
opposite DHFR subunit (Fig. 3). Side chains from Leu2020 and
Phe1980 on the linker helix ﬁt into this hydrophobic groove, with the
latter participating in aromatic stacking with Tyr47 of the opposite
protomer. Crystallographically, this interaction remains intact
whether BbDHFR-TS is in the apo state or bound to small molecules
and may serve to stabilize the holoenzyme. The DHFR subunit also
creates a binding surface with the TS subunit and part of the linker of
the same protomer. This interface involves a combination of hydro-
phobic and polar interactions between Thr166–Val182 in the terminal
edge of the DHFR  -sheet, Pro219–His226 of the linker and residues
Ile470–Arg476 and Glu497–Val500 of TS, all within the same
protomer (Fig. 3). This nonspeciﬁc but structural nature of the
DHFR-TS interface has been observed previously for bifunctional
DHFR-TS enzymes from other species and involves varying contri-
butions from the linker depending on the source organism (Knighton
et al., 1994; O’Neil et al., 2003; Yuvaniyama et al., 2003; Yuthavong et
al., 2005).
3.2. Comparison of DHFR and TS from B. bovis and other organisms
The variability in amino-acid identity for DHFR enzymes from
different organisms has afforded opportunities to develop potent
drugs with host–pathogen selectivity, such as pyrimethamine and
cycloguanil, which are both used to treat malaria (Kompis et al., 2005;
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Figure 3
Key subunit interfaces for structures of BbDHFR-TS. Top left, arginine side chains from the opposite TS subunit (yellow) directly bind the terminal dUMP phosphate in the
active site of one protomer (violet). Top right, the linker region from one protomer (gray) ﬁts into a hydrophobic groove created by DHFR from the opposite protomer
(green). Bottom, binding surface between the DHFR (pink), TS (yellow) and linker (gray) regions of protomer B of apo BbDHFR-TS, with labels for hydrogen-bonding
residues. All distances are measured in A ˚ . These ﬁgures were created using PDB entries 3i3r, 3k2h and 3nrr with PyMOL (DeLano, 2002).Yuthavong et al., 2005). However, resistance can arise in response
to drug pressure, and mutations in the DHFR subunit of DHFR-TS
from P. falciparum (PfDHFR-TS) proven to confer resistance to
pyrimethamine and cycloguanil include A16V/S, N51I, D54N, C59R,
S108T/N and I164L (Foote et al., 1990; Peterson et al., 1988;
Yuvaniyama et al., 2003). Four residues (Ile34, Arg42, Thr69 and
Leu123) of wild-type DHFR-TS from the Texas T2Bo strain of
B. bovis (Brayton et al., 2007) correspond to those seen in a quad-
ruple drug-resistant mutant of PfDHFR-TS. This identity, together
with the high structural homology between DHFRs of both
organisms, suggest that cycloguanil and pyrimethamine may have low
efﬁcacy in targeting DHFR-TS from B. bovis.
The TS subunit of BbDHFR-TS possesses much higher sequence
identity than the DHFR subunit when compared with monomeric
DHFR and dimeric TS enzymes from human, yeast and bacteria, as
well as other bifunctional DHFR-TS enzymes (Table 3). The TS
domain of BbDHFR-TS possesses a catalytic cysteine (Cys393) which
bonds to C6 of dUMP, and a nearby tyrosine (Tyr333) which is
purported to abstract the C5 proton from the substrate during cata-
lysis (Carreras & Santi, 1995). An asparagine which is fully conserved
structural communications
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Table 3
Percentage identity matrix for DHFR (bottom left) and TS (top right) enzymes among species.
Asterisks (*) denote bifunctional DHFR-TS. Calculated after alignment using ClustalX 2.0.10 (Larkin et al., 2007).
C. hominis* P. falciparum* B. bovis* T. cruzi* L. major* T. gondii* H. sapiens S. aureus L. casei E. coli
Cryptosporidium hominis*5 4 5 7 5 5 5 4 5 5 5 7 4 7 5 0 5 0
Plasmodium falciparum*3 1 6 3 5 2 5 4 6 1 5 6 4 6 4 6 4 8
Babesia bovis*4 0 3 3 5 1 5 3 5 3 5 6 4 8 4 9 4 8
Trypanosoma cruzi*3 5 2 9 2 7 8 0 5 9 6 3 4 7 4 8 5 0
Leishmania major*3 3 2 5 2 45 3 5 9 6 1 4 9 4 9 4 9
Toxoplasma gondii*4 3 2 8 3 5 3 23 2 6 6 4 54 5 4 7
Homo sapiens 35 31 33 31 29 37 49 50 54
Staphylococcus aureus 31 28 33 25 23 27 28 30 60
Lactobacillus casei 25 23 25 22 22 26 24 64 60
Escherichia coli 33 28 34 33 30 36 29 41 29
Figure 4
Binding modes of pemetrexed (left) and raltitrexed (right) in the active sites of the TS (top) and DHFR (bottom) subunits of BbDHFRTS. Active sites from protomer A (TS,
violet; DHFR, green; ligands, white) are overlaid with active sites from protomer B (TS, yellow; DHFR, pink; ligands, black) for both complexes. Raltitrexed (RTX) and
pemetrexed (PTX) bind the TS active site identically in both protomers of both structures. For the DHFR subunit, the glutamate tail of PTX is consistent across both
protomers of 3k2h, creating a salt bridge with Arg83. The glutamate tail of RTX is rotated relative to PTX in the DHFR subunit, resulting in loss of the Arg83 salt bridge, and
binds in different conformations to each protomer of 3nrr. This ﬁgure was created using PyMOL (DeLano, 2002).across all eukaryotes is also present in BbDHFR-TS (Asn310);
this residue is conserved as a tryptophan in all known prokaryotic
sequences. Both Asn310 in eukaryotes and the equivalent tryptophan
in prokaryotes appear to perform the same function in TS, which is
to bind to the carboxy-terminus and partition off the ternary complex
from solvent (Fig. 4). It has been suggested that a tryptophan in this
location does more to orient the folate (and perhaps to exclude larger
antifolate inhibitors)thanthecorrespondingasparaginein eukaryotes
(Costi et al., 2005). Wild-type BbDHFR-TS also possesses Ala278 and
Ser281, nonconserved residues which usually appear as phenyl-
alanine and glycine in other eukaryotes, respectively, whether they be
dimeric ThyA or bifunctional DHFR-TS. These residues lie at one
end of the cofactor-binding site near the solvent-exposed glutamate
tail of mTHF and other folate-like molecules when bound. Alanine
and serine at these positions are associated with higher TS reaction
rates, as observed for DHFR-TS from C. hominis relative to L. major
and those of other species (Atreya & Anderson, 2004; Doan et al.,
2007).
3.3. Ligand-bound complexes of BbDHFR-TS
We have solved three structures of BbDHFR-TS, one free of
ligands and two complexes with fully occupied DHFR and TS active
sites. The apo structure of BbDHFR-TS (PDB entry 3i3r) contains no
visible substrates or cofactors, only chlorine ions in the arginine-rich
phosphate-binding sites for dUMP in the TS subunits (Fig. 2). The
two complex structures of BbDHFR-TS have two ligands bound
to each subunit of each protomer in the asymmetric unit. The ﬁrst
complex structure (PDB entry 3k2h) contains the antifolate peme-
trexed and dUMP bound in the TS subunit and pemetrexed and
NADP bound in the DHFR subunit. The second ligand-bound
structure (PDB entry 3nrr) contains raltirexed rather than peme-
trexed in both folate sites, as well as dUMP and NADP. The apo state
of BbDHFR-TS is structurally similar to the bifunctional enzyme
when partially or fully occupied with ligands, but is more disordered.
The apo crystal generates higher B factors than those of ligand-bound
BbDHFR-TS (Table 2) and has more missing residues than either of
the quinternary complexes. The model for the apo structure has three
chain breaks per polypeptide chain, two of which are within segments
of the linker chain that traverses from one protomer to the other.
One of these chain breaks (Lys187–Pro196) is missing from all three
BbDHFR-TS structures and appears to be completely surrounded by
solvent molecules, making no other contacts with the protein (Figs. 2
and 3). The third disordered section of the apo structure comprises
a loop which usually contacts the glutamate tail of dihydrofolate
(DHF), closing the gate once bound.
Pemetrexed (Taylor et al., 1992) and raltitrexed (Jackman et al.,
1991) are folate analogs designed as antitumour agents and currently
approved for use in some countries for treatment of cancer (Hagner
& Joerger, 2010; Jackman & Calvert, 1995). Both compounds are
nanomolar inhibitors of thymidylate synthase and have been struc-
turally characterized in complex with human TS (Phan et al., 2001;
Sayre et al., 2001). Like the native cofactor mTHF, all antifolate
compounds bind to TS only after the substrate has bound and are
sequestered from solvent by a ﬂexible C-terminal tail which closes
upon ternary-complexformation (Carreras&Santi,1995).Depending
on the source organism, raltitrexed has a twofold to 50-fold higher
activity against TS versus DHFR, while pemetrexed tends to inhibit
both enzymes equally well. This unique speciﬁcity proﬁle has sparked
greater interest in developing potent multitarget antifolates for the
treatment of malaria and other infectious diseases (Gangjee et al.,
2005, 2008; Shih et al., 1997). When both protomers from each
BbDHFR-TS homodimer are compared, the complexed states reveal
verysimilarmodesofbindingforbothdrugstotheTSsubunit(Fig.4).
The pteroyl-like groups of pemetrexed and raltitrexed are parallel to
the uracil ring of dUMP when bound, mimicking the pteridine ring
of the native cofactor mTHF. Although the ’ angle of the C-terminal
Ala511 in one protomer of the raltitrexed complex is rotated by
approximately 30  relative to the other, this has no effect on the
virtually identical binding modes of raltitrexed in both TS subunits
in a single crystal structure. Both drug molecules are also observed in
the DHFR subunit but appear to bind this substrate pocket with
different geometries (Fig. 4). The bound conformation of pemetrexed
is virtually identical in both DHFR protomers but differs slightly
from that of raltitrexed, which itself has two different binding modes
for its glutamate tail. The pteroyl-like groups of raltitrexed and
pemetrexed again recapitulate the pteridine-ring structure of the
native substrate DHF when binding to DHFR. In this case, no
structural accommodation is made to differentiate between polar
(C2–NH2) and nonpolar (C2–CH3) scaffold differences, a chemical
distinction often associated with the lower DHFR afﬁnity measured
for raltitrexed (Gangjee et al., 2008; Kamen et al., 2000). However, the
para-substitution pattern of benzamide in pemetrexed allows the
formation of a salt bridge between the  -COOH of its glutamate tail
and the Arg83 side chain. This is in contrast to the 2,5-disubstituted
thiophene ring of raltitrexed with no salt bridge to Arg83. The ﬁve-
membered ring of raltitrexed causes a >90  rotation and a 6.8 A ˚
translation of its  -COOH group relative to pemetrexed (Fig. 4).
Moreover, the glutamate tail of raltitrexed is shifted between
protomers of DHFR in the same crystal, with both making hydrogen
bonds to Arg42 but only one contacting the N
" atom of His33 (Fig. 4).
These interactions are not seen for pemetrexed, in which the gluta-
mate group is in essentially the same conformation in both DHFR
protomers, despite the differences in side-chain rotamers observed
for the nearby Arg39 and Arg42. The loss of salt bridge and distinct
binding modes of raltitrexed thus provide a structural basis for its
lower DHFR afﬁnity relative to pemetrexed, independent of the
reduced chemical afﬁnity associated with its C2-methylpteroyl scaf-
fold.
4. Conclusions
We have crystallized and structurally characterized DHFR-TS from
B. bovis in the apo state and in complex with substrates, cofactors
and antifolate compounds. The different complexation states of this
bifunctional enzyme reveal features similar to those seen in other
organisms and conﬁrm its place with the enzymes from other api-
complexans in the long-linker family of DHFR-TS. The antifolate
drugs pemetrexed and raltitrexed are capable of binding to the
DHFR and TS subunits of BbDHFR-TS, indicating a degree of
afﬁnity for both drugs to both folate-binding sites. The high
sequential and structural homology between DHFR-TS of B. bovis
and that of P. falciparum suggest that effective DHFR-TS inhibitors
for malaria may prove to be effective in treating babesiosis. However,
mutations which arose in response to drug pressure and have
conferred resistance to cycloguanil and pyrimethamine in malarial
DHFR-TS already exist as wild-type residues in B. bovis.T h i s
suggests a reduced chance of such existing drugs working effectively
to treat babesiosis by the same mechanism of action. These three
structures comprise a signiﬁcant portion of the B. bovis structures
currently available in the PDB and provide a structural starting point
for rational drug-design efforts aimed at developing novel com-
pounds which may lead to new treatments for babesiosis infections.
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